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Aggressive and optimal cytoreduction in the surgical management
of primary epithelial ovarian cancer (EOC) has been shown to improve
survival outcomes in advanced stage disease (Chi et al., 2006;
Eisenhauer et al., 2008; Eisenkop et al., 1998; Aletti et al., 2006). In the
upper abdomen, liver resection, diaphragm stripping and resection, sple-
nectomy, distal pancreatectomy, and porta hepatis lymphadenectomy
have been described in EOC debulking and are now routinely utilized
when indicated (Eisenhauer et al., 2006). We present a case of stage IIIC
papillary serous ovarian cancer that required pancreaticoduodenectomy
(Whipple procedure) to both relieve a malignant bowel obstruction
and achieve optimal cytoreduction.
Case report
A 58 year old woman with a history of stage I microinvasive inﬁl-
trating ductal right breast carcinoma managed with conservative
surgery, radiation, and tamoxifen one year prior presented to her
primary medical oncologist with early satiety, nausea, bilious
vomiting, and abdominal distention. Computed tomography (CT) of
the abdomen and pelvis revealed ascites, an omental cake, peritoneal
carcinomatosis, and periumbilical lymphadenopathy. Her stomach⁎ Corresponding author at: 200 1st St. SW, Rochester,MN55905, USA. Fax:+1 507 266
9300.
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identiﬁed (Fig. 1). Her CA 125 level was 1850 U/mL. A CT-guided
omental ﬁne needle aspiration was initially determined to be consis-
tent with metastatic breast cancer. She received one dose of the ﬁrst
planned cycle of paclitaxel and carboplatin with alleviation of the
vomiting. Shortly thereafter on further immunohistological compar-
ison, the omental metastasis showed strong nuclear staining for
Wilm's tumor 1 (WT-1) and was negative for gross cystic disease
ﬂuid protein 15 (GCDFP 15) and mammoglobin. Her initial breast
cancer was negative for WT-1 and focally positive for GCDFP 15
and mammoglobin, supporting the diagnosis of a new ovarian or pri-
mary peritoneal carcinoma.
She was referred to gynecologic oncology for consideration
of cytoreductive surgery. She was deemed a candidate for primary
cytoreduction, underwent an exploratory laparotomy, and was found
to have a 4 cm right ovarian cancer, a large omental cake attached to
the transverse mesocolon, right diaphragm involvement, and diffusely
scattered 1 to 2 mm nodules within the pelvis, on the appendix, and
on the small bowel mesentery. Optimal cytoreduction to 1 to 2 mm of
residual disease appeared feasible based on these initial ﬁndings at
exploration. A thickening near the site of bowel malrotation and head
of the pancreas was palpable. The etiology of the mass was unclear at
the beginning of the procedure.
Surgical cytoreduction included a total abdominal hysterectomy, bi-
lateral salpingo-oophorectomy, omentectomy, appendectomy, liver
mobilization with subsequent stripping of the right hemidiaphragm,
transverse colocolostomy, and bilateral pelvic and para-aortic lymphad-
enectomy. Frozen pathology conﬁrmed a high-grade papillary serous
carcinoma arising from the right ovary. During the right para-aortic dis-
section, the proximal gonadal vessels were found to be encased by the
palpable paraduodenal thickening. Careful dissection revealed bulky
para-aortic lymphadenopathy that involved the head of the pancreas
and the second portion of the duodenum. It was intimately attached
to the duodenal serosa, causing near-complete luminal stricture, and
appeared to be causing a high-grade bowel obstruction. General surgery
was consulted intraoperatively anddetermined that itwas not possible to
resect the lymphadenopathy and alleviate the obstruction without a
pancreaticoduodenectomy. A pylorus-sparing pancreaticoduodenectomy
(Whipple procedure)with cholecystectomywas performed. The remain-
ing pancreas was soft and normal; and the pancreatic duct diameter was
also normal at 3 mm. Her small bowel was determined to be partially
malrotated with nearly the entire duodenum on the right side of thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. High grade small bowel obstruction at the level of the duodenum (black arrow) secondary to peripancreatic lymphadenopathy (white arrow).
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papillary serous ovarian cancer.
During her initial postoperative hospitalization, she developed a
pancreaticojejunostomy anastomotic leak that was controlled with a
drain. She was managed with broad-spectrum antibiotics, octreotide,
and total parenteral nutrition (TPN) until bowel function returned. She
was dismissed home on postoperative day #16. Just over one month
after surgery, she was readmitted with a pancreatico-cutaneous ﬁstula
communicating through her midline incision. She was managed with
bowel rest, TPN, octreotide, a proton-pump inhibitor, broad-spectrum
antibiotics, wound debridement with lateralization of the ﬁstula, and a
vacuum wound device. During this hospitalization, a pelvic abscess
was also diagnosed and managed with CT-guided drainage and antibi-
otics. She was discharged on hospital day #27.
Her ﬁstula healed, and two weeks after dismissal, she began 6
planned intravenous (IV) cycles of paclitaxel and carboplatin. After
each treatment, she had serous drainage from her ﬁstula site for a
few days. Nevertheless, she had no interruptions in her planned
treatments and had a CA 125 of 2.2 U/mL upon completion of adju-
vant therapy.
Given her personal history of breast and ovarian carcinoma, she
underwent BRCA testing. She was found to have a deleterious BRCA2
mutation, namely R2336H (7235G N A). Additionally, a BRCA1 variant
of unknown signiﬁcance was identiﬁed (IVS11 + 3A N G), which has
since been reclassiﬁed as a suspected deleterious mutation.
Shewas disease free for ﬁfteenmonths after initial diagnosis and for
nine months after completion of platinum-based chemotherapy. Ab-
dominal bloating and constipation prompted a CT that demonstrated
ascites and mesenteric nodules; her CA 125 was 56 U/mL. She received
carboplatin and gemcitabine and, after three cycles, developed a
carboplatin allergy and switched to gemcitabine and bevacizumab. Dur-
ing the ﬁrst cycle, she was admitted for a small bowel obstruction with-
out a clear transition point that was treated conservatively. Shortly
thereafter her treatment was interrupted by osteomyelitis associated
with a large abscess anterior to the pubic symphysis that required sur-
gical debridement and antibiotics.She elected not to receive chemotherapy for the next elevenmonths
until she developed progressive disease in an axillary lymph node, the
left rectus, and the vaginal cuff. Systemic treatment with various
regimens of liposomal doxorubicin, topotecan, bevacizumab, cyclo-
phosphamide, protein-bound paclitaxel, AT-406, carboplatin with de-
sensitization, anastrozole, and capecitabine were administered over
the next 43 months with short responses at best. When she developed
rectovaginal bleeding secondary to tumor involvement, palliative radi-
ation with 3000 cGy in 10 fractions was administered.
Within two months of radiation, she developed a partial bowel ob-
struction secondary to a rectosigmoid stricture which was managed
conservatively with placement of two colonic stents. After discharge
from the hospital, she began ABT-888 on a compassionate use basis,
however discontinued it after two months due to weakness and
tumor progression. She enrolled in hospice 6.5 years after her primary
cytoreduction and passed away shortly thereafter.
Discussion
Advanced-stage EOC often involves the omentum and can involve
contiguous upper abdominal organs such as the spleen, colon, and pan-
creas (Eisenhauer et al., 2006; Hoffman et al., 2007). The utility of ag-
gressive, multi-organ resection (MOR) has been explored in several
primary malignancies that can present with advanced abdominal dis-
ease. While morbidity and mortality can be relatively high, aggressive
surgical approaches in select patients can lead to prolonged survival
(Lygidakis et al., 2007).
Improved survival outcomes in advanced-stage ovarian cancer cor-
relate with increasing completeness of primary cytoreduction (Chi
et al., 2006; Eisenhauer et al., 2008; Eisenkop et al., 1998; Aletti et al.,
2006). Several aggressive surgical techniques have been described in
the management of EOC and are being used more often in the attempts
to achieve optimal cytoreduction (Eisenhauer et al., 2006). EOC often
involves the retroperitoneum and upper abdomen and can be intimate-
ly associated with the pancreas and small bowel. The presence of bulky
upper abdominal disease does not appear to portend a worse prognosis
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the utility of upper abdominal disease debulking, including distal pan-
createctomy for pancreatic tail metastases, have been published with
progression-free and overall survival rates similar to optimally-
cytoreduced advanced-stage EOC not requiring upper abdominal dis-
ease resection (Eisenhauer et al., 2006; Yildirim & Sanci, 2005).
We present a patientwith stage IIIC EOC and BRCA 1 and BRCA2mu-
tations who required pancreaticoduodenectomy to both alleviate a
high-grade bowel obstruction and achieve optimal cytoreduction. To
our knowledge, pancreaticoduodenectomy has not been previously de-
scribed as part of the MOR often required for primary cytoreduction of
EOC. One recognized complication of pancreaticoduodenectomy is
pancreaticojejunostomy anastomotic leak. Bulky lymphadenopathy
encasing the second portion of the duodenum and involving the head
of the pancreas caused the high-grade bowel obstruction in our patient.
Her pancreas was otherwise normal, which increased her risk of
pancreaticojejunostomy leak; the incidence of leak increases signiﬁ-
cantly in patients with a small pancreatic duct (≤3 mm) and soft
gland texture. Fortunately, the vast majority of these leaks can be man-
aged conservatively (Cullen et al., 1994; Yang et al., 2005).
Despite developing postoperative complications and experiencing a
delay in initiating adjuvant chemotherapy, our patient lived for
6.5 years after her initial diagnosis and primary cytoreduction. This
case illustrates the impact of aggressive upper abdominal debulking
and potential role of pancreaticoduodenectomy in the management of
primary EOC.Conﬂict of interest
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